Skip to Main Content

When it comes to developing cancer treatments, the pharmaceutical industry has long prioritized drugs for conditions that disproportionately turn up in patients in the West.

That has meant less attention to certain types of cancer, like those of the stomach and esophagus, that disproportionately affect patients in China.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.